Conference Coverage

Buprenorphine linked to less neonatal abstinence syndrome than methadone


 

AT AAP 2017

CHICAGO – Methadone was associated with a significantly higher incidence of neonatal abstinence syndrome (NAS), compared with babies born to mothers who took buprenorphine for opioid maintenance therapy during pregnancy, a retrospective study of 204 neonates revealed.

Interestingly, among babies who developed the syndrome, the duration of treatment and length of stay did not differ significantly between groups.

“We found buprenorphine decreases [the incidence of] NAS,” said Alla Kushnir, MD, an attending neonatologist at Cooper University Hospital in Camden, N.J. The findings also demonstrate that physicians can expect to see “about the same withdrawal once they withdraw,” regardless of whether the mother took methadone or buprenorphine during pregnancy.

“We can’t make it better, but we can prevent some neonatal abstinence syndrome,” Dr. Kushnir said in an interview at the annual meeting of the American Academy of Pediatrics.

Dr. Ravi Bhavsar

Reported cases of neonatal abstinence syndrome (NAS) nationwide increased threefold between 2000 and 2009, jumping from 1.2 cases to 3.4 cases per 1,000 births/year. Affected newborns typically develop symptoms 48-72 hours after birth, including nervous system irritability, autonomic system dysfunction, and gastrointestinal and respiratory abnormalities.

The infants in the study were admitted to the neonatal ICU between July 2010 and June 2016. The mothers self-reported prenatal use of methadone, buprenorphine, other opioids and/or various illicit drugs, or tested positive on a urine screen during pregnancy. In the methadone group, 81% of infants developed NAS, compared with 50% of those in the buprenorphine group. The higher likelihood of developing NAS from methadone-treated mothers was statistically significant (P less than .001).

The study population included some women who reported taking additional drugs. Among 65 infants born to women who combined methadone with other agents, 58 (89%) developed NAS. In addition, all seven infants (100%) born to women who took buprenorphine and other drugs developed the syndrome.

“Methadone was the clear bad guy in terms of incidence” between the two drugs, said Ravi Bhavsar, MBBS, a research assistant at the hospital.

Among the infants who developed NAS symptoms, the hospital length of stay and duration of medical treatment – indicators of syndrome severity – did not differ significantly (P = .015).

“This study also tells us that more research needs to be done,” Dr. Bhavsar said. Methadone is a mainstay of opioid maintenance therapy, he added, and additional evidence is warranted before shifting recommendations toward buprenorphine.

Dr. Kushnir and Dr. Bhavsar reported having no relevant financial disclosures.

Recommended Reading

FDA has the resources to answer questions about medicines and pregnancy
MDedge ObGyn
Prenatal methadone maintenance linked to poorer child neurodevelopment
MDedge ObGyn
Early neuroimaging essential for Zika-exposed neonates
MDedge ObGyn
Extreme caffeine use in early pregnancy risks offspring behavioral disorders
MDedge ObGyn
Researchers identify ‘congenital NAD deficiency disorders’
MDedge ObGyn
Opening the door to gene editing?
MDedge ObGyn
Cerebral palsy rate down in children born very or moderately preterm
MDedge ObGyn
Postpartum depression screening in well-child care appears promising
MDedge ObGyn
Study: Don’t separate NAS infants from moms
MDedge ObGyn
Domperidone appears safe galactagogue for mothers and infants
MDedge ObGyn